Table 1.
SPTAN1 in various cancer types.
| Tumor Type | Changes in SPTAN1 | References |
|---|---|---|
| Colorectal cancer (CRC) | SPTAN1 upregulation | [28] |
| SPTAN1 downregulation in MLH1-deficient CRC | [29] | |
| SPTAN1 upregulation in sporadic CRC, SPTAN1 downregulation in MLH1-deficient CRC | [30] | |
|
| ||
| Gastric cancer | SPTAN1 upregulation | [28, 31, 32] |
|
| ||
| Lung cancer | SPTAN1 upregulation | [33] |
| SPTAN1 mutations and downregulation | [34] | |
|
| ||
| Breast cancer | SPTAN1 upregulation (cytoplasmic) | [28, 35, 36] |
|
| ||
| Bladder cancer | Recurrence-associated SPTAN1 alterations | [37] |
|
| ||
| Prostate cancer | SPTAN1 downregulation in lung metastasis, SPTAN1 as progression gene | [38] |
|
| ||
| Cutaneous tumors | SPTAN1 upregulation (cytoplasmic) | [39] |
|
| ||
| Soft-tissue tumors | SPTAN1 upregulation in more aggressive mesenchymal tumors | [40] |
|
| ||
| Ovarian cancer | SPTAN1 upregulation after chemotherapy | [41] |
|
| ||
| Atypical chronic myeloid leukaemia (aCML) | Novel CSF3R-SPTAN1 fusion gene | [42] |
|
| ||
| Non-Hodgkin lymphoma | SPTAN1 as target protein in postchemotherapy | [43] |
|
| ||
| Non-Hodgkin lymphoma, acute lymphoblastic leukaemia (ALL) | SPTAN1 upregulation after chemotherapy in nuclear area | [44] |